Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Imedla Angelica Cirilo

Internal Medicine Manchester, CT Medical Doctor

NPI 1962780940 CMS profile 504929

629 Middle Tpke E, Manchester, CT 06040

Open in the dashboard

General payments

$1,226

69 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Imedla Angelica Cirilo of Manchester, CT is reported in the CMS Open Payments database as having received $1,226 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $22 1
2020 General $202 12
2019 General $1,002 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Imedla Angelica Cirilo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Imedla Angelica Cirilo were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Imedla Angelica Cirilo Internal Medicine median Middle half National median
2019 $1,002 $159 $48–$570 $163
2020 $202 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $22 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $321 18 payments
  2. Pfizer Inc. $210 8 payments
  3. Allergan Inc. $132 9 payments
  4. Scilex Pharmaceuticals Inc. $114 6 payments
  5. GlaxoSmithKline, LLC. $111 4 payments
  6. Lilly USA, LLC $96 6 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $94 7 payments
  8. Merck Sharp & Dohme Corporation $76 6 payments
  9. Sanofi-Aventis U.S. LLC $18 1 payment
  10. Kowa Pharmaceuticals America, Inc. $15 1 payment
  11. Other $39 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,226 69 payments
Products named General payments · program years 2019–2024
  1. ELIQUIS $210 8 payments
  2. Tresiba $193 9 payments
  3. Victoza $151 7 payments
  4. Xultophy 100/3.6 $151 7 payments
  5. Ozempic $129 9 payments
  6. VRAYLAR $108 7 payments
  7. TRULICITY $96 6 payments
  8. XIFAXAN $94 7 payments
  9. SHINGRIX $90 3 payments
  10. JANUVIA $76 6 payments
  11. Other $880 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

5,411

Median for Internal Medicine: 777

Drug cost

$416,057

Median for Internal Medicine: $73,373

Branded share of claims

17.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 72 $82,631
Jardiance Empagliflozin Brand 31 $54,183
Eliquis Apixaban Brand 46 $52,041
Trulicity Dulaglutide Brand 27 $49,126
Januvia Sitagliptin Phosphate Brand 26 $41,610
Mounjaro Tirzepatide Brand 34 $35,454
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $19,414
Advair Hfa Fluticasone Propion/Salmeterol Brand 15 $5,915
Synthroid Levothyroxine Sodium Brand 58 $5,342
Duloxetine Hcl Generic 104 $4,864

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$78,305

Of which drugs: $5,250

Medicare patients

206

Average age 75

Services billed

883

139 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 43%
Diabetes 23%
Depression 23%
Ischemic heart disease 21%
Atrial fibrillation 17%
Chronic kidney disease 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 25 25 $2,046

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $22
$22 30 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record